Tapan Kadia, MD, received his medical degree from Robert Wood Johnson Medical School in Piscataway, NJ. After this he completed a clinical internship, a clinical residency and a chief residency at Baylor College of Medicine in Houston, TX.
Dr Kadia currently serves as an Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, TX. He has authored over 160 peer-reviews articles, as well as numerous abstracts, and has presented his research at many national and international meetings.
Speaking on personalized medicine for AML and ALL
Dr Kadia is actively involved in both clinical and translational research for the treatment of patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In particular, his research focuses on developmental therapeutics, including personalized medicine, biologically rationalized targeted therapy, and longer term maintenance strategies for AML and ALL.
Dr Kadia is the principal investigator on numerous clinical in AML, T-cell leukemias and bone marrow failure syndromes.